Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Accelerates Portfolio Shift After Pain-Drug Setback

Vertex enters the coming months with momentum in cystic fibrosis franchises and an active pipeline, while a mid-stage pain trial failure forces a strategic pivot that can influence near-term commercial cadence.

Recent News

On August 4th Vertex reported Q2 results that beat expectations, citing revenue near $2.96 billion and EPS of $4.52; the same day the company announced it would discontinue development of its mid‑stage pain candidate following a non‑statistically significant result in that study. Additional media coverage through September noted continued institutional stake adjustments and commentary on product launches and regulatory activity.

Technical Analysis

Directional indicators present a bullish tilt inside an emerging trend: ADX at 22.89 signals an emerging trend, DI+ at 15.10 shows a dip-and-reversal (bullish), and DI− at 24.09 shows a peak-and-reversal (bullish). Together these dynamics imply directional strength building toward the upside while trend strength remains moderate.

MACD sits negative at −$6.58 but recently crossed above its signal line (signal −$7.09), a bullish momentum signal that suggests momentum has shifted toward buyers despite the negative absolute MACD level; this supports short-term upward pressure against the prevailing valuation backdrop.

MRO at −27.14 indicates price below target and therefore potential for an increase; the negative oscillator complements the MACD cross and directional indicators by implying mean reversion toward model targets.

RSI at 43.0 with a dip-and-reversal indicates renewed upward pressure from lower readings, consistent with the MACD and MRO setup for a near-term recovery in price momentum.

Price sits at $385.74 under the 20‑day average $387.57, the 50‑day $407.37 and the 200‑day $447.22; the 12‑day EMA shows a dip-and-reversal. Bollinger upper bands lie near $394.71–$401.84 while the super trend upper level appears at $395.63. Those band and average levels identify resistance bands that the current momentum would need to overcome to extend gains, creating a scenario where short-term rallies could seek the $388–$396 zone before meeting heavier selling pressure given the valuation profile.

 


Fundamental Analysis

Revenue totaled $2,964,700,000 with revenue growth at 7.02%. YoY revenue growth value shows −519.92% and QoQ revenue growth shows −244.17% as reported. Total gross profit registered $2,557,200,000 with a gross margin of 86.26%, and operating margin at 38.93%.

EPS came in at $4.52 versus an estimate of $4.25, an EPS surprise of 6.35%, and forward EPS of $4.69. EBIT reached $1,286,700,000 with an EBIT margin of 43.40%, which sits above the industry peer mean of −89.06% and above the industry peer median of 23.76%.

Cash and short‑term investments total $6,382,800,000 with cash $4,972,200,000; the cash ratio measures 154.23% and the current ratio 251.98%, supporting liquidity. Total debt stands at $1,527,400,000, debt to assets 6.35%, and debt to EBITDA 1.14x, indicating modest leverage relative to capital structure.

Free cash flow reached $927,400,000 with a free cash flow yield of 0.85% and free cash growth of 19.17%. Return on equity equals 6.01% and return on assets 4.40%, while operating leverage reads 10.75.

Valuation metrics show elevated multiples: a trailing P/E of 102.08, forward P/E of 97.34, price-to-book 6.38 and price‑to‑sales 36.96. WMDST values the stock as over‑valued given these premium multiples alongside current cash flow yields and profitability metrics.

MOST-RECENT QUARTERLY REPORT
REPORT PERIOD ENDING: 2025-06-30
REPORT DATE: 2025-08-04
NEXT REPORT DATE: 2025-11-03
CASH FLOW  Begin Period Cash Flow 4.7 B
 Operating Cash Flow 1.1 B
 Capital Expenditures -145.70 M
 Change In Working Capital -132.40 M
 Dividends Paid
 Cash Flow Delta 296.6 M
 End Period Cash Flow 5.0 B
 
INCOME STATEMENT REVENUE
 Total Revenue 3.0 B
 Forward Revenue 863.0 M
COSTS
 Cost Of Revenue 407.5 M
 Depreciation 51.7 M
 Depreciation and Amortization 51.7 M
 Research and Development 978.4 M
 Total Operating Expenses 1.8 B
PROFITABILITY
 Gross Profit 2.6 B
 EBITDA 1.3 B
 EBIT 1.3 B
 Operating Income 1.2 B
 Interest Income 122.4 M
 Interest Expense 3.7 M
 Net Interest Income 118.7 M
 Income Before Tax 1.3 B
 Tax Provision 250.1 M
 Tax Rate 19.493 %
 Net Income 1.0 B
 Net Income From Continuing Operations 1.0 B
EARNINGS
 EPS Estimate 4.25
 EPS Actual 4.52
 EPS Difference 0.27
 EPS Surprise 6.353 %
 Forward EPS 4.69
 
BALANCE SHEET ASSETS
 Total Assets 24.0 B
 Intangible Assets 1.5 B
 Net Tangible Assets 15.7 B
 Total Current Assets 10.4 B
 Cash and Short-Term Investments 6.4 B
 Cash 5.0 B
 Net Receivables 1.9 B
 Inventory 1.5 B
 Long-Term Investments 1.1 B
LIABILITIES
 Accounts Payable 442.3 M
 Short-Term Debt
 Total Current Liabilities 4.1 B
 Net Debt
 Total Debt 1.5 B
 Total Liabilities 6.9 B
EQUITY
 Total Equity 17.2 B
 Retained Earnings 11.3 B
VALUATION & PER-SHARE METRICS EQUITY & PER-SHARE METRICS
 Book Value Per-Share 67.01
 Shares Outstanding 256.293 M
 Revenue Per-Share 11.57
VALUATION
 Market Capitalization 109.6 B
 Enterprise Value 104.7 B
 Enterprise Multiple 78.246
Enterprise Multiple QoQ -48.969 %
Enterprise Multiple YoY -324.847 %
Enterprise Multiple IPRWA VRTX: 78.246
high: 47.216
median: 14.143
mean: 5.404
low: -68.907
 EV/R 35.324
CAPITAL STRUCTURE
 Asset To Equity 1.399
 Asset To Liability 3.503
 Debt To Capital 0.082
 Debt To Assets 0.064
Debt To Assets QoQ -11.836 %
Debt To Assets YoY 37.058 %
Debt To Assets IPRWA high: 0.995
mean: 0.204
median: 0.07
VRTX: 0.064
low: 0.0
 Debt To Equity 0.089
Debt To Equity QoQ -11.043 %
Debt To Equity YoY 40.757 %
Debt To Equity IPRWA high: 1.577
mean: 0.27
VRTX: 0.089
median: 0.057
low: -1.039
PRICE-BASED VALUATION
 Price To Book (P/B) 6.38
Price To Book QoQ -15.414 %
Price To Book YoY -21.871 %
Price To Book IPRWA high: 16.592
VRTX: 6.38
mean: 5.102
median: 4.07
low: -10.064
 Price To Earnings (P/E) 102.075
Price To Earnings QoQ -14.412 %
Price To Earnings YoY -380.067 %
Price To Earnings IPRWA VRTX: 102.075
high: 44.732
mean: -11.195
median: -19.0
low: -73.374
 PE/G Ratio 9.009
 Price To Sales (P/S) 36.961
Price To Sales QoQ -17.71 %
Price To Sales YoY -18.952 %
Price To Sales IPRWA high: 517.227
mean: 58.723
VRTX: 36.961
median: 19.711
low: 0.25
FORWARD MULTIPLES
Forward P/E 97.336
Forward PE/G 8.591
Forward P/S 126.977
EFFICIENCY OPERATIONAL
 Operating Leverage 10.745
ASSET & SALES
 Asset Turnover Ratio 0.126
Asset Turnover Ratio QoQ 3.59 %
Asset Turnover Ratio YoY 5.211 %
Asset Turnover Ratio IPRWA high: 0.388
VRTX: 0.126
mean: 0.114
median: 0.104
low: -0.001
 Receivables Turnover 1.603
Receivables Turnover Ratio QoQ -1.199 %
Receivables Turnover Ratio YoY 4.509 %
Receivables Turnover Ratio IPRWA high: 7.487
VRTX: 1.603
median: 1.422
mean: 1.383
low: 0.012
 Inventory Turnover 0.285
Inventory Turnover Ratio QoQ 0.717 %
Inventory Turnover Ratio YoY -33.786 %
Inventory Turnover Ratio IPRWA high: 2.946
mean: 0.649
median: 0.415
VRTX: 0.285
low: 0.006
 Days Sales Outstanding (DSO) 56.919
CASH CYCLE
 Cash Conversion Cycle Days (CCC) 304.74
Cash Conversion Cycle Days QoQ 26.874 %
Cash Conversion Cycle Days YoY 53.056 %
Cash Conversion Cycle Days IPRWA high: 1258.184
VRTX: 304.74
mean: 188.019
median: 126.183
low: -1350.846
CAPITAL DEPLOYMENT
 Cash Conversion Ratio 0.471
 CapEx To Revenue -0.049
 CapEx To Depreciation -2.818
 
CAPITAL, LIQUIDITY & COVERAGE CAPITAL STRUCTURE
 Total Capital 17.2 B
 Net Invested Capital 17.2 B
 Invested Capital 17.2 B
 Net Tangible Assets 15.7 B
 Net Working Capital 6.3 B
LIQUIDITY
 Cash Ratio 1.542
 Current Ratio 2.52
Current Ratio QoQ -4.755 %
Current Ratio YoY -0.038 %
Current Ratio IPRWA high: 25.128
mean: 4.044
VRTX: 2.52
median: 2.092
low: 0.021
 Quick Ratio 2.158
Quick Ratio QoQ -5.629 %
Quick Ratio YoY -4.658 %
Quick Ratio IPRWA high: 14.041
mean: 3.054
VRTX: 2.158
median: 1.788
low: 0.021
COVERAGE & LEVERAGE
 Debt To EBITDA 1.141
 Cost Of Debt 0.188 %
 Interest Coverage Ratio 347.757
Interest Coverage Ratio QoQ 42.251 %
Interest Coverage Ratio YoY -201.819 %
Interest Coverage Ratio IPRWA high: 940.414
VRTX: 347.757
mean: 19.322
median: 0.121
low: -1465.352
 Operating Cash Flow Ratio 0.206
TIMING / LIQUIDITY
 Days Payables Outstanding (DPO) 111.524
DIVIDENDS
 Dividend Coverage Ratio
 Dividend Payout Ratio
 Dividend Rate
 Dividend Yield
PERFORMANCE GROWTH
 Asset Growth Rate 5.053 %
 Revenue Growth 7.021 %
Revenue Growth QoQ -244.168 %
Revenue Growth YoY -519.916 %
Revenue Growth IPRWA high: 303.4 %
mean: 22.048 %
median: 12.272 %
VRTX: 7.021 %
low: -259.856 %
 Earnings Growth 11.33 %
Earnings Growth QoQ 463.682 %
Earnings Growth YoY -103.066 %
Earnings Growth IPRWA high: 155.0 %
VRTX: 11.33 %
median: 11.05 %
mean: 1.352 %
low: -181.25 %
MARGINS
 Gross Margin 86.255 %
Gross Margin QoQ -0.738 %
Gross Margin YoY 0.363 %
Gross Margin IPRWA high: 100.0 %
VRTX: 86.255 %
median: 77.498 %
mean: 76.788 %
low: -77.751 %
 EBIT Margin 43.401 %
EBIT Margin QoQ 63.932 %
EBIT Margin YoY -133.958 %
EBIT Margin IPRWA high: 338.783 %
VRTX: 43.401 %
median: 23.755 %
mean: -89.061 %
low: -5123.44 %
 Return On Sales (ROS) 38.931 %
Return On Sales QoQ 47.048 %
Return On Sales YoY -130.461 %
Return On Sales IPRWA high: 89.247 %
VRTX: 38.931 %
median: 23.652 %
mean: -92.797 %
low: -5698.0 %
CASH FLOW
 Free Cash Flow (FCF) 927.4 M
 Free Cash Flow Yield 0.846 %
Free Cash Flow Yield QoQ 35.36 %
Free Cash Flow Yield YoY -126.646 %
Free Cash Flow Yield IPRWA high: 36.371 %
VRTX: 0.846 %
median: 0.284 %
mean: -0.462 %
low: -74.318 %
 Free Cash Growth 19.172 %
Free Cash Growth QoQ -67.042 %
Free Cash Growth YoY -104.15 %
Free Cash Growth IPRWA high: 165.621 %
VRTX: 19.172 %
mean: 2.257 %
median: 0.941 %
low: -193.262 %
 Free Cash To Net Income 0.898
 Cash Flow Margin 28.802 %
 Cash Flow To Earnings 0.827
VALUE & RETURNS
 Economic Value Added 0.04
 Return On Assets (ROA) 4.403 %
Return On Assets QoQ 54.708 %
Return On Assets YoY -126.986 %
Return On Assets IPRWA high: 36.544 %
VRTX: 4.403 %
median: 1.616 %
mean: -1.961 %
low: -68.545 %
 Return On Capital Employed (ROCE) 6.466 %
 Return On Equity (ROE) 0.06
Return On Equity QoQ 53.497 %
Return On Equity YoY -124.726 %
Return On Equity IPRWA high: 1.117
VRTX: 0.06
median: 0.04
mean: 0.003
low: -1.572
 DuPont ROE 6.135 %
 Return On Invested Capital (ROIC) 6.031 %
Return On Invested Capital QoQ 53.305 %
Return On Invested Capital YoY -89.023 %
Return On Invested Capital IPRWA high: 53.785 %
VRTX: 6.031 %
median: 3.175 %
mean: 0.903 %
low: -71.959 %

Six-Week Outlook

Technical signals favor a short‑term bullish bias: MACD crossing above its signal, DI+/DI− dynamics both signaling bullish, negative MRO implying upside toward model value, and RSI recovering from lower levels. Expect price action to probe the near resistance band between approximately $388 and $396, defined by the 20‑day average, short‑term EMA, and upper Bollinger region. The over‑valued fundamental valuation and wide gap to the 50‑ and 200‑day averages increase the likelihood that moves above the mid‑$390s meet selling pressure; conversely, failure to sustain the current momentum would keep the bias rangebound toward the low‑$380s. Monitor momentum indicators for confirmation of any sustained break beyond the upper band or reversion below short‑term averages.

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) develops and commercializes therapies targeting cystic fibrosis (CF) and other serious diseases. The company markets several CF treatments, including TRIKAFTA/KAFTRIO for patients aged two and older with at least one F508del mutation, SYMDEKO/SYMKEVI for those aged six and older, ORKAMBI for patients one year and older, and KALYDECO for patients with specific mutations. Vertex’s research pipeline includes VX-522, an mRNA therapeutic for CF, currently in Phase 1 trials, and VX-548, a non-opioid treatment for acute and neuropathic pain, in Phase 3 trials. The company also explores Exa-cel for sickle cell disease and transfusion-dependent beta thalassemia, in Phase 2/3 trials. Other projects include inaxaplin for APOL1-mediated kidney diseases, VX-880 and VX-264 for Type 1 Diabetes, and several cancer treatments in various trial phases. Vertex collaborates with companies like CRISPR Therapeutics AG, Moderna, Inc., and others to enhance its therapeutic offerings. Founded in 1989, Vertex Pharmaceuticals maintains its headquarters in Boston, Massachusetts, and distributes products through specialty and retail channels in the United States.



© 2025 WMDST — The World’s Most Dangerous Swing Trader. All rights reserved.